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ARTICLE
Cancer cell-expressed SLAMF7 is not required for
CD47-mediated phagocytosis
Yuan He1, Renee Bouwstra1, Valerie R. Wiersma1, Mathilde de Jong1, Harm Jan Lourens1, Rudolf Fehrmann2,
Marco de Bruyn3, Emanuele Ammatuna1, Gerwin Huls1, Tom van Meerten1 & Edwin Bremer1
CD47 is a prominent new target in cancer immunotherapy, with antagonistic antibodies
currently being evaluated in clinical trials. For effective evaluation of this strategy it is crucial
to identify which patients are suited for CD47-targeted therapy. In this respect, expression of
the pro-phagocytic signal SLAMF7 on both macrophages and cancer cells was recently
reported to be a requisite for CD47 antibody-mediated phagocytosis. Here, we demonstrate
that in fact SLAMF7 expression on cancer cells is not required and does not impact on CD47
antibody therapy. Moreover, SLAMF7 also does not impact on phagocytosis induction by
CD20 antibody rituximab nor associates with overall survival of Diffuse Large B-Cell Lym-
phoma patients. In contrast, expression of CD47 negatively impacts on overall and pro-
gression free survival. In conclusion, cancer cell expression of SLAMF7 is not required for
phagocytosis and, in contrast to CD47 expression, should not be used as selection criterion
for CD47-targeted therapy.
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The CD47/SIRP-α axis has been established as an importantregulator of innate anti-cancer immunity, with many if notall malignancies overexpressing the receptor CD47 that
binds to phagocyte-expressed SIRP-α1–3. CD47-mediated trig-
gering of SIRP-α inhibits phagocytic removal of cancer cells and
reduces the immunogenic processing of cancer cells by macro-
phages and dendritic cells2,4,5. Consequently, both innate and
adaptive anticancer immunity is suppressed. Correspondingly,
high CD47 expression is associated with poor clinical prognosis
in various malignancies6,7.
CD47/SIRP-α-blocking antibodies enhance antibody-
dependent cellular phagocytosis (ADCP) of cancer cells upon
co-treatment with anticancer monoclonal antibodies6,8. For
instance, co-treatment of anti-CD20 antibody rituximab with
the CD47-blocking murine antibody B6H12 synergized the
phagocytic elimination of xenografted human CD20pos non-
Hodgkin lymphoma (NHL) cancer cells in murine models in
the absence of noticeable toxicity6. Correspondingly, huma-
nized CD47-blocking antibodies are currently being evaluated
in phase-1 clinical trials (NCT02216409/NCT02367196). Thus,
CD47 is a prominent new target in cancer immunotherapy,
particularly in B-cell malignancies, in which e.g. combination of
a CD47 antibody with the CD20 antibody rituximab is being
explored in clinical trials.
However, several reports have highlighted potential immu-
noregulatory proteins that may impact on the efﬁcacy of CD47-
targeted therapy9–11. For instance, expression of LILRB1 on
macrophages inhibited induction of cancer cell phagocytosis by a
CD47-blocking antibody by direct binding to MHC class I and
inhibition of macrophage activity, which was reversed by
antibody-mediated blocking of LILRB111. Further, it was recently
reported that the expression of the pro-phagocytic receptor
SLAMF7 on macrophages and cancer cells was required for
phagocytosis induction upon treatment with a CD47 blocking
therapeutic antibody10. Speciﬁcally, macrophages obtained from
SLAMF7 knock-out mice proved to be defective in phagocytosis
of cancer cells. Further, SLAMF7 expression on hematopoietic
cancer cells was reported as a requisite for phagocytosis upon
treatment with a CD47 blocking antibody. The premise arising
from this ﬁnding is that only hematopoietic cancers that express
high levels of SLAMF7 are suitable targets for CD47 blocking
therapy. As such, diffuse large B-cell lymphoma (DLBCL), the
most common subtype of non-Hodgkin’s lymphoma (NHL), was
identiﬁed as a suitable target for CD47 blocking therapy based on
its high SLAMF7 mRNA levels.
In the current report, we aimed to further delineate the
potential role of SLAMF7 expression on cancer cells for CD47-
targeted and monoclonal antibody-based therapy in DLBCL.
Surprisingly, we found that surface expression of SLAMF7 is not
required for phagocytosis of DLBCL cells and does not correlate
with phagocytosis by CD47 blocking antibody treatment. Simi-
larly, phagocytosis induction upon treatment with CD20 antibody
rituximab alone or in combination with CD47 antibody does not
correlate with, nor requires, cancer cell surface expression of
SLAMF7. Correspondingly, SLAMF7 mRNA expression does not
correlate with overall survival (OS) after R-CHOP treatment in a
large transcriptomic dataset of gene expression proﬁles (GEP) of
680 DLBCL patients, whereas expression of CD47 does. Taken
together, expression of SLAMF7 is not required nor impacts on
phagocytosis upon CD47 antibody treatment and should not be
used as a selection criterion for CD47-targeted antibody therapy.
Rather, our data indicate that the expression level of CD47 itself
may be a primary selection criterion in DLBCL.
Results
CD47-mediated phagocytosis does not require SLAMF7 on
DLBCL. Since SLAMF7 was postulated to be critical for CD47
antibody-mediated phagocytosis and DLBCL was postulated to
be a prime target for CD47 antibody therapy, we ﬁrst deter-
mined expression of SLAMF7 in DLBCL cell lines and primary
DLBCL cells and found surface expression of SLAMF7 in only 1
of the 7 DLBCL cell lines tested (Fig. 1a, b), with mRNA for
SLAMF7 being detected only in 2 out of 7 cell lines (Fig. 1c).
Importantly, surface expression of SLAMF7 was also not
detected on primary patient-derived DLBCL or mantle cell
lymphoma (MCL) cells (Fig. 1d). In contrast, expression of high
levels of SLAMF7 was detected on the surface of macrophages,
including on primary macrophages obtained from DBLCL and
MCL patients (Fig. 1e, f). To investigate if tumor-expressed
SLAMF7 was a requisite for phagocytosis of DLBCL cells upon
CD47 targeting, we generated type 1 macrophages (MØ) as the
prototype pro-inﬂammatory macrophage subtype associated
with anti-cancer activity. These macrophages were mixed with
ﬂuorescently labeled DBLCL cells and phagocytosis upon CD47
targeting was assessed. Importantly, despite the absence of
cancer cell-expressed SLAMF7, CD47 targeting signiﬁcantly
induced phagocytosis of 7 out of 7 ﬂuorescently (V450)-labeled
DLBCL lines by macrophages when using F(ab′)2 fragments
(Fig. 2a and Supplementary Movies 1 and 2). Of note, F(ab′)2
fragments were used for this analysis in order to delineate the
impact of CD47 blocking in the absence of potential Fc/FcR-
mediated effects that may occur when using full antibodies. To
further validate engulfment of tumor cells, cells were stained
with either V450 or PHrodo-Red dye, a dye only emitting
ﬂuorescence after internalization. In both settings, phagocytosis
of DLBCL cells in CD11b-stained macrophages was detected
after treatment with CD47 F(ab)′2 (Fig. 2b). Assessment of
phagocytosis using ﬂow cytometry yielded similar results
(Fig. 2c), with signiﬁcant phagocytic uptake of six out of seven
DLBCL cell lines (Fig. 2d). Of note, staining for caspase-3-
positive apoptotic cells, using IncuCyte caspase-red staining,
identiﬁed that CD47 F(ab)′2 treatment triggered phagocytosis
of viable cells (Supplementary Figure 1A). Moreover, in the 2 h
time-line of this assay no additional caspase-positive (and/or
fragmented caspase-negative) apoptotic bodies were detected
(data not shown). Thus, CD47 blockade triggered phagocytosis
of viable DLBCL cells.
It is well-established that various macrophage subtypes can be
detected in the tumor micro-environment (TME), with the
predominant focus in literature being on the so-called
M2 subtype that is thought to contribute to the immunosuppressive
milieu in the tumor12. However, also non-polarized M0 as well as
pro-inﬂammatory M1 polarized macrophages have been reported
in the TME of various cancers12. Correspondingly, we used
CIBERSORT13,14 to estimate the fraction of different macrophage
subtypes in the DLBCL micro-environment in a large gene
expression database of DLBCL (Fig. 2e). Therefore, the impact of
targeting of CD47 using F(ab′)2 fragments was also assessed for M0
and M2 macrophages, with increased phagocytosis of DLBCL cells
upon treatment being detected for macrophages differentiated into
M1 (LPS/IFN-y), M2 (IL-10), and M0 (M-CSF/GM-CSF) macro-
phages (Fig. 2f, g). Thus, for all of the macrophage subtypes found
in the TME of DLBCL, SLAMF7 expression on cancer cells is not
required for anticancer activity upon CD47 targeting, with M2
macrophages appearing to respond more effectively to CD47-
targeting than M1 macrophages while having lower SLAMF7
expression (Supplementary Figure 1B, C).
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SLAMF7 does not correlate with CD47-mediated phagocytosis.
Next, we evaluated whether phagocytic activity of a clinically
relevant CD47 targeting antibody might similarly be independent
of SLAMF7 expression on cancer cells. Hereto, we used the
antibody Inhibrix, an IgG4 containing antibody currently being
evaluated in clinical trials for B cell malignancies including
DBLCL (NCT02953509). Use of an IgG4 domain limits unwanted
Fc/FcR-interactions and should largely restrict activity of the
antibody to blocking of CD47/SIRPα interaction. Importantly,
treatment with this clinically relevant CD47 antibody was com-
parable in efﬁcacy to that of treatment with the CD47 F(ab′)2
(Fig. 3a). Moreover, inhibrix also effectively induced phagocytosis
upon treatment of SLAMF7-negative primary patient-derived
DLBCL and MCL cells by autologous patient-derived macro-
phages, yielding signiﬁcant increases in phagocytosis of ~15% and
8%, respectively (Fig. 3b). Thus, the effect of a clinically relevant
CD47 blocking IgG4 antibody is mediated by blocking of the
SIRPα/CD47 interaction and does not require expression of
SLAMF7 on cancer cells.
To further investigate the potential relevance of cancer-
expressed SLAMF7, other B cell NHL cell lines cells with varying
levels of SLAMF7 expression were evaluated for phagocytosis
upon CD47-targeting. Speciﬁcally, the NHL cell line Raji, BJAB,
and Z138 signiﬁcantly expressed cell surface SLAMF7 (Fig. 3c),
whereas Daudi and Ramos had weak and non-signiﬁcant
expression of SLAMF7 (Fig. 3c). Nevertheless, all of these cell
lines were signiﬁcantly phagocytosed upon treatment with CD47
F(ab′)2 irrespective of expression of SLAMF7 (Fig. 3d). Corre-
spondingly, expression of SLAMF7 did not at all correlate with
the level of experimental phagocytosis induced by treatment with
CD47 F(ab′)2 (Fig. 3e, r2= 0.00012), nor with CD47 antibody
Inhibrix (Fig. 3f, r2= 0.0016). Taken together, these data clearly
demonstrate that expression of SLAMF7 on hematopoietic cancer
cells is not required for phagocytosis by macrophages upon CD47
blocking therapy. Similarly, SLAMF7 expression (or lack thereof)
did not correlate with the extent of phagocytosis induced upon
treatment of a B-NHL cell line panel with CD20 antibody
rituximab alone (Fig. 3g) or upon combination treatment with
rituximab and inhibrix (Fig. 3h, i). Indeed, combined treatment
failed to reach a statistically signiﬁcant beneﬁcial effect in the
SLAMF7-positive cell line Oci-Ly3, whereas signiﬁcant improve-
ment was detected in the SLAMF7-negative cell lines (Fig. 3i).
Thus, in B-NHL cell lines the expression of SLAMF7 is not
required for induction of phagocytosis by CD47 antibodies, nor
for phagocytosis induction upon treatment with rituximab.
SLAMF7 mRNA does not impact survival in R-CHOP-treated
DBLCL. Next, we evaluated the potential clinical impact of
SLAMF7 on CD47 blocking, speciﬁcally in the context of com-
bination with the clinically relevant antibody rituximab, which is
part of the standard-of-care treatment for DLBCL patients. Of
note, combination of rituximab with CD47 blocking antibodies is
currently being investigated in several phase I clinical trials
(NCT02367196; NCT02953509). In a large transcriptomic dataset
of GEP of 680 DLBCL patients that were treated with R-CHOP
(Supplementary Tables 1 and 2), the OS of patients with high
SLAMF7 expression did not differ from that of patients with low
expression of SLAMF7 (Fig. 4a, p= 0.2). In a similar analysis with
CD47, patients with high mRNA expression of CD47 did have a
signiﬁcantly worse OS than patients with low expression of CD47
(Fig. 4b, p= 0.0009). Further, when CD47 expression was ana-
lyzed within the SLAMF7 high and low population, no signiﬁcant
impact of SLAMF7 on OS could be detected (Fig. 4c). Similarly,
















































































































































Fig. 1 SLAMF7 expresses on primary macrophages but not on DLBCL cells. a Representative graph of SLAMF7 expression in two DLBCL lines (SLAMF7
positive in OCI-ly3 cells, SLAMF7 negative in U2932 cells). b Surface expression levels of SLAMF7 in a panel of seven DBLCL cell lines (n= 3). c mRNA
expression levels of SLAMF7 in a panel of seven DLBCL cell lines (n= 3). d Expression of SLAMF7 on primary patient-derived DLBCL cells.
e Representative graph of SLAMF7 expression on macrophages from the DLBCL patient or healthy donors. f Quantiﬁcation of SLAMF7 expression in
DLBCL lines, primary patient-derived DLBCL cells, macrophages from healthy donors and macrophages from patients with B-cell malignancies. Error bars
stand for standard deviation (SD)
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when SLAMF7 expression was analyzed within the CD47 high
and CD47 low quartiles, high expression of CD47 associated with
poor survival, but was not further impacted by high or low
expression of SLAMF7 (Fig. 4d). Thus, SLAMF7 does not impact
on treatment outcome in a large cohort of R-CHOP-treated
patients. Of note, the outcome of this SLAMF7 GEP analysis
should in future studies be conﬁrmed with a similar analysis of
SLAMF7 at the protein level, particularly as we did not detect
SLAMF7 on the primary DLBCL sample (Fig. 1d).
Discussion
The data presented here demonstrate that surface expression of
SLAMF7 on hematopoietic cancer cells, speciﬁcally on B cell
malignant cells, is not required for phagocytosis upon CD47
blocking treatment, nor upon combination treatment with
rituximab. Further, mRNA expression of SLAMF7 is not pre-
dictive for survival in a large cohort of R-CHOP-treated DLBCL
patients, whereas mRNA expression of CD47 is predictive. The
important corollary of these ﬁndings is that cancer cell expression
of SLAMF7 does not associate with or predict for therapeutic
effects of CD47-targeting drugs. As such, expression of
SLAMF7 should not be used as an inclusion/exclusion criterion
for clinical trials that evaluate CD47 targeting.
The ﬁndings presented here clearly contrast to the conclusions
arrived at by Chen et al., with their conclusion being that
SLAMF7 expression on both macrophages and tumor cells is a
requisite for phagocytosis upon CD47 antibody treatment both
in vitro and in vivo10. However, only two B-cell lines were pre-
sented as examples of susceptible SLAMF7-positive cells, with
DLBCL being proposed as a suitable target for CD47 blocking
therapy solely based on high SLAMF7 mRNA levels in a patient
cohort. Using the same antibody clone as Chen et al., only 1 out
of 7 DLBCL cell lines was found to detectably express cell surface
SLAMF7. Notably, also no SLAMF7 surface expression was
observed on primary patient-derived leukemic DLBCL and MCL
cells. Moreover, the F(ab′)2 of CD47 antibody inhibrix as well as
the full antibody inhibrix-induced signiﬁcant phagocytosis in all
these DLBCL lines. In line with this, there was no correlation






































































































































































































































































































Fig. 2 Tumor-expressing SLAMF7 is not required for induction of phagocytosis upon CD47-targeting treatment in DLBCL cells. a Percentage of
phagocytosis of DLBCL cell lines by allogeneic human macrophages primed with LPS/IFN-γ upon 3 h treatment with F(ab′)2 of anti-CD47 antibody inhibrix
(CD47 F(ab′)2) vs. untreated cells (n= 3–5). b Representative microscopy pictures of phagocytosis of tumor cells by macrophages primed with LPS/IFN-γ
upon 3 h treatment with CD47 F(ab′)2 (left, MØ+V450-labeled OCIly3 cells, right, MØ+ pHrodogreen-labeled SUDHL5 cells). Scale bar= 20 µm.
c Representative graphs of ﬂow cytometric analysis for phagocytosis of tumor cells by macrophages with LPS/IFN-γ upon 3 h treatment with CD47 F(ab′)2
(left, MØ+ SUDHL5, right, MØ+ SUDHL10). d Quantiﬁcation of phagocytosis of DLBCL cell lines by ﬂow cytometric analysis. Experimental setting is the
same as in (a) (n= 3–4). e Percentage of different types of macrophages from cibersort fraction of DLBCL biopsies (n= 1804). f Percentage of
phagocytosis of DLBCL cell lines by allogeneic type 0 human macrophages upon 3 h treatment with F(ab′)2 of anti-CD47 antibody inhibrix (CD47 F(ab′)2)
vs. untreated cells (n= 4–6). g Percentage of phagocytosis of DLBCL cell lines by allogeneic human macrophages primed with IL-10 upon 3 h treatment
with F(ab′)2 of anti-CD47 antibody inhibrix (CD47 F(ab′)2) vs. untreated cells (n= 4–6). Statistics was performed using paired Student’s t-test. n.s.= not
signiﬁcant, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Error bars stand for standard deviation (SD)
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Fig. 3 Efﬁcacy of CD47-targeting antibodies in B-cell malignant cells does not correlate with SLAMF7 expression. a Experimental phagocytosis of DLBCL
lines by macrophages either upon CD47 F(ab′)2 treatment or inhibrix treatment (n= 3). Box plot contains center line representing median and whiskers
representing 5–95%. b Representative microscopy pictures of phagocytosis of primary DLBCL cells by autologous macrophages upon 3 h treatment with
inhibrix. Quantiﬁcation of phagocytosis of primary DLBCL and MCL cells by autologous macrophages. c Quantiﬁcation of surface SLAMF7 expression on
ﬁve NHL lines (n= 3). d Percentage of phagocytosis of NHL cell lines by allogeneic human macrophages primed with LPS/IFN-γ upon 3 h treatment with F
(ab′)2 of anti-CD47 antibody inhibrix (CD47 F(ab′)2) vs. untreated cells (n= 3–4). e Correlation between SLAMF7 expression and the percentage of
experimental phagocytosis induced by CD47 F(ab′)2 in NHL and DLBCL cell panel (n= 3). f Correlation between SLAMF7 expression and the percentage
of experimental phagocytosis induced by anti-CD47 antibody inhibrix in DLBCL cell panel (n= 3–4). g Correlation between SLAMF7 expression and the
percentage of experimental phagocytosis induced by Rituximab in NHL and DLBCL cell panel (n= 3). h Correlation between SLAMF7 expression and the
percentage of experimental phagocytosis induced by the combinatory treatment of Rituximab and Inhibrix in DLBCL cell panel (n= 3). i Experimental
phagocytosis of tumor cells by macrophages upon RTX treatment or combination treatment with inhibrix (n= 3). Experiments with primary patient-derived
samples were performed in triplicates. Statistics was performed using paired Student’s t-test. n.s.= not signiﬁcant, *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. Error bars stand for standard deviation (SD)
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antibodies treatment in a cohort of DLBCL and NHL lines (r2=
0.00012). Thus, expression of SLAMF7 on cancer cells is not a
requisite for phagocytosis upon CD47 antibody treatment.
Expression of SLAMF7 on cancer cells also did not impact on
the in vitro phagocytic activity of macrophages upon treatment
with the CD20 antibody rituximab alone, or in combination with
CD47 antibody inhibrix. These data correspond to the lack of
association of SLAMF7 mRNA expression with patient survival
after rituximab and CHOP treatment as evaluated in a large
cohort of 680 DLBCL patients. Of note, in this cohort, expression
of CD47 did associate with OS in R-CHOP-treated patients, as
patients that express high CD47 have a worse outcome. Thus,
these data suggest that the therapeutic effect of rituximab may
potentially be augmented by co-treatment with CD47 blocking
antibody. In contrast, the data provided here do not support
SLAMF7 as a potential selection marker for response, nor do
these data suggest that combination of rituximab with, e.g.
SLAMF7 targeting antibodies, such as elotuzumab, would be a
potential combinatorial approach to augment rituximab activity
given the lack of expression in the majority of cell lines tested
here. In this respect, combination of rituximab with CD47 anti-
body targeting is being clinically evaluated for patients with
relapsed/refractory B-cell non-Hodgkin’s lymphoma
(NCT02953509). Of note, although for DLBCL the expression of
SLAMF7 does not impact on phagocytosis upon CD47-targeting
treatment, its impact especially in multiple myeloma (MM) may
well be different. Indeed, surface expression of SLAMF7 is well-
established on both normal plasma cells and MM and SLAMF7
has been exploited as tumor target in MM using elotuzumab15.
Indeed, heavily pre-treated MM patients who received a combi-
nation of elotuzumab, lenalidomide, and dexamethasone had a
signiﬁcant prolonged progression free survival compared to
lenalidomide and dexamethasone alone16.
Expression of SLAMF7 on macrophages was reported to be a
requisite for phagocytosis upon CD47-targeting therapy, as
SLAMF7 knock-out in murine macrophages abrogated phago-
cytosis upon CD47 targeting. Further, co-treatment with a
blocking SLAMF7 antibody inhibited CD47-mediated phagocy-
tosis of cancer cells by human macrophages10. Interestingly, in a
transcriptome analysis of polarized macrophages the expression
of SLAMF7 was found to be clearly associated with the M1
polarization status of macrophages17. In line with this,
expression of SLAMF7 was higher on M1-than on M2-polarized
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Fig. 4 mRNA expression of SLAMF7 does not, but of CD47 does, associate with survival in DLBCL patients. a Kaplan–Meijer curve analysis of survival of
DLBCL patients within high and low SLAMF7-expressing quartiles. b Kaplan–Meijer curve analysis of survival of DLBCL patients within high and low CD47-
expressing quartiles. c Kaplan–Meijer curve analysis of survival of DLBCL patients within high and low SLAMF7-expressing quartiles additionally sorted on
high and low expression of CD47. d Kaplan–Meijer curve analysis of survival of DLBCL patients within high and low CD47-expressing quartiles additionally
sorted on high and low expression of SLAMF7
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pro-inﬂammatory M1 polarized macrophages have been reported
in the TME of various cancers, the predominant focus in litera-
ture is on the so-called M2 subtype that is thought to particularly
contribute to the immunosuppressive milieu12. In our experi-
ments, M2 macrophages proved to be equally effective or perhaps
slight more effective than M1 macrophages in triggering CD47
antibody-dependent phagocytosis of DBLCL cells (Supplemen-
tary Figure 1B). This ﬁnding is in agreement with a report that
M2 macrophages more effectively phagocytosed rituximab-
opsonized tumor cells than M1 macrophages18. Taken together,
these data suggest that the expression level of SLAMF7 on mac-
rophages may not impact on macrophage activity after CD47
targeting. Thus, it will be of interest to further determine whether
SLAMF7 expression on human M2-polarized and M1-polarized
macrophages indeed is critical for phagocytosis, e.g. by knock-
down studies in cord blood stem cell-derived macrophages.
In conclusion, mRNA and/or protein expression levels of
SLAMF7 on hematopoietic cancer cells should not be used as
selection/exclusion criterion for future clinical studies that eval-
uate the therapeutic potential of CD47-blockade or the combi-
nation with CD47 blocking therapy.
Methods
Reagents and antibodies. PE-labeled anti-human SLAMF7 antibody (clone,
162.1) and PE-labeled isotype control were purchased from Biolegend. APC-
labeled anti-CD3, FITC-labeled anti-CD19 and APC-labeled anti-CD47 were
purchased from Immunotools (Germany). FITC-labeled anti-CD20 was purchased
from Thermoﬁsher. Alexa594-labeled CD11b was purchased from Biolegend. Anti-
human CD47 IgG4 antibody (Inhibrix, clone B6H12) was generated in-house by
Aduro Biotech Europe (ABE). F(ab′)2 of Inhibrix was prepared with Pierce F(ab′)2
preparation kit. F(ab′)2 generation was conﬁrmed by staining for human IgG4
(Supplementary Figure 1D). Cell proliferation dye V450 was purchased from
Thermoﬁsher. Phrodo Green pH indicators was purchased from Thermoﬁsher.
Lymphoprep was purchased from Axis-Shield PoC AS, Norway. pHrodo Green
intracellular pH indicator was purchased from ThermoFisher. RNeasy mini kit was
purchased from Qiagen. iScript cDNA Synthesis Kit was purchased from Bio-Rad.
Cell lines and primary patient-derived B-cell malignancies. Cell lines used in
this study were obtained from the American Type Culture Collection (Manassas,
VA) or the Deutsche Sammlung from Microorganimen und Zellculturen
(Braunschweig, Germany) and cultured at 37 °C in humidiﬁed 5% CO2 containing
atmosphere. DLBCL cell lines SUDHL2, SUDHL5, SUDHL10, and OCI-ly3 were
cultured in RPMI culture medium (Lonza) supplemented with 20% fetal calf serum
(Thermo Scientiﬁc) in the present of glutamine (100 µM, Gibco). DLBCL cell lines
SUDHL4, SUDHL6, and U2932 and NHL cell lines BJAB, Daudi, Ramos, Raji, and
Z138 were cultured in RPMI 1640 culture medium supplemented with 10% fetal
calf serum (Thermo Scientiﬁc). Peripheral blood mononuclear cells (PBMCs) from
patients’ blood were isolated by using gradient centrifugation with lymphoprep and
phenotyped for CD3, CD19, CD20, CD47, and SLAMF7. This study was carried
out in The Netherlands in accordance with International Ethical and Professional
Guidelines (the Declaration of Helsinki and the International Conference on
Harmonization Guidelines for Good Clinical Practice). The use of anonymous rest
material is regulated under the code for good clinical practice in the Netherlands.
Informed consent was waived in accordance with Dutch regulations.
Preparation of primary human macrophages. Monocytes were enriched from
isolated PBMCs, obtained from healthy donors after informed consent, by MACS
sorting using CD14 magnetic beads (Miltenyi Biotec). Monocytes were differ-
entiated into macrophages (M0) in RPMI 1640 culture medium+ 10% FCS sup-
plemented with GM-CSF (50 ng/ml) and M-CSF (50 ng/ml) for 7 days. To generate
type 1 macrophages, M0 cells were primed by LPS and IFN-γ for additional 24 h.
To generate type 2 macrophages, M0 cells were primed by IL-10 for an additional
48 h. To generate cord blood-derived monocytes, CD34+ stem cells were isolated
by MACS sorting using CD34 magnetic beads, followed by stem cell culture in the
presence of cytokine mixture for 14 days19. Subsequently, monocytes were dif-
ferentiated to type 0 macrophage as described above. To isolate patient-derived
monocytes, PBMCs from patients were seeded into six-well plates for 3–4 h after
which ﬂoating cells were removed. Monocytes were then gently washed with PBS
(2–3 times) and cultured with fresh medium containing GM-CSF and M-CSF as
described above.
Surface expression of SLAMF7 on B-cell malignant cells. Both malignant B-cells
(5 × 105/ml) and primary patient-derived blasts were stained with anti-SLAMF7
antibody (2.5 µg/ml) or isotype control on ice for 1 h. Subsequently, cells were
washed with ice-cold PBS (three times) and resuspended in fresh medium. Cellular
surface expression of SLAMF7 was then determined by ﬂow cytometry (Accuri,
BD).
qRT-PCR analysis in DLBCL lines. Cells were washed with cold PBS and then cell
pellet was harvested by centrifugation at 5000 rpm for 15 min. Next, RNA was
isolated from cell pellet by RNeasy mini Kit according to manufacturer’s intro-
ductions, and subsequently cDNA was synthesized from quantiﬁed RNA with
iScript cDNA Synthesis Kit according to manufacturer’s introductions. qRT-PCR
analysis for SLAMF7 was performed on a Bio-Rad thermal cycler using SsoAd-
vanced™ Universal SYBR® Green Supermix. A 20 μl reaction mixture contained: 10
μl 2 × SYBR Green Master, 0.4 μl forward primer (10 μM), 0.4 μl reverse primer
(10 μM), 2 μl cDNA, and 7.2 μl dd H2O in a 96-well plates. The ampliﬁcation
conditions were as follows: 95 °C for 3 min, 40 cycles of 95 °C for 5 s and 58 °C for
15 s. Melting curve was analyzed to determine primer speciﬁcity. 2−ΔCT method
was used for calculating with reference gene RPL27. Primers used were: SLAMF7
(forward AGAACACAGAGTACGACACAAT/reverse CAGTGGAGTAAACCGT
ATTTGC), RPL27 (forward CCGGACGCAAAGCTGTCATCG/reverse
CTTGCCCATGGCAGCTGTCAC).
In vitro macrophage phagocytosis assay. Macrophages were harvested and pre-
seeded at 1.5 × 104 cells/well in 96-well plates. Tumor cells were labeled with cell
proliferation dye V450 (Thermoﬁsher) or pHrodo green pH indicator (Thermo-
ﬁsher) according to manufacturer’s instructions. Subsequently, tumor cells were
incubated with or without anti-human CD47 IgG4 antibody (Inhibrix) or F(ab′)2
of Inhibrix (both at 5 μg/ml) on ice for 1 h. Tumor cells were washed with cold PBS
(two times) and added to pre-seeded macrophages (effector to target ratio of 1:5)
and incubated for 3 h at 37 °C. Tumor cells were gently removed by washing with
PBS 2–3 times and phagocytosis was analyzed by ﬂuorescent microscopy (Leica,
DM6000) or confocal microscopy (Leica SP8). For visualization of macrophages,
residual cells were stained with anti-human CD11b-alexa594 (1 μg/ml) at RT for
45 min. The percentage of phagocytosis was calculated by counting the number of
macrophages containing V450-labeled tumor cells per 100 macrophages. Each
condition was quantiﬁed by evaluating three randomly chosen ﬁelds of view.
Retrospective mRNA analysis of DLBCL patients. Publicly available raw
microarray expression data of DLBCL samples platforms (Affymetrix HG-U133A
(GPL96) and Affymetrix HG-U133 Plus 2.0 (GPL570)) were extracted from the
Gene Expression Omnibus (GEO)20. To identify DLBCL samples, the Simple
Omnibus Format in Text (SOFT) ﬁles that contain metadata of each individual
sample, were retained if they contained at least one of the keywords; DLBCL or
DLCL. Next manually, pubmed identiﬁers pointing to relevant published manu-
scripts were used to conﬁrm the samples represented de novo DLBCL. Cell lines
and animal samples were excluded. Only rituximab, cyclophosphamide, doxor-
ubicin, vincristine, and prednisone-treated DLBCL patient samples were used for
further analysis. Principal component analysis (PCA) on the sample correlation
matrix was used for quality control21. The ﬁrst principal component (PCqc) of
such an expression microarray correlation matrix describes nearly always a con-
stant pattern that dominates the data. This ﬁrst PCA explains 80–90% of the total
variance, which is independent of the biological nature of the sample being pro-
ﬁled. The correlation of each individual microarray expression proﬁle with this
PCqc can be used to detect outliers, as arrays of lesser quality will have a lower
correlation with the PCqc. We removed samples that had a correlation R < 0.8.
Probe 213857_s_at (CD47 gene) and 219159_s_at (SLAMF7 gene) were used for
the analyses. For patient characteristics, see Supplementary Tables 1 and 2. For
GEO accession numbers, and distribution of SLAMF7 and CD47 mRNA expression
see Supplementary Figure 2A–C.
Estimated immune cell type fractions. CIBERSORT was used to estimate the
fraction of the three subtypes of macrophages (M0, M1, and M2). CIBERSORT is a
method for characterizing cell composition of complex tissues from their GEP that
has been shown to have strong agreement with ground truth assessments in bulk
tumors. The 680 DLBCL GEP was used in combination with the leukocyte gene
signature matrix, LM22, to distinguish 22 hematopoietic cell types, including the
three subtypes of macrophages. For each sample (DLBCL GEP), the sum of all
estimated hematopoietic cell-type fraction equals 1.
Statistical analysis. Effect of CD47 antibody on phagocytosis was determined by
paired Student’s t-test, based on a minimum of 3–5 different donors. Time-to-
event data was analyzed using the Kaplan–Meier method and the log-rank test to
compare the survival distributions between the different groups. OS was deﬁned as
the time from primary diagnosis to death from any case. Survivors were censored
on the last date that they were known to be alive or when followed up longer than 6
years. Patients were sorted based on CD47 expression or SLAMF7 expression. The
25% of patients with lowest and highest expression were used to determine
inﬂuence of expression on survival. All statistical analysis are tested two-sided and
p-values < 0.05 were considered statistically signiﬁcant. All analyses were con-
ducted using SPSS statistics (version 23.0 Armonk, NY, IBM Corp.), STATA 14
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(StataCorp LP, College Station, TX), and GraphPad Prism (GraphPad Prism
[version 7.0b]; GraphPad Software, La Jolla, CA).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The raw microarray expression data of DLBCL samples platforms (Affymetrix HG-
U133A 316 (GPL96) and Affymetrix HG-U133 Plus 2.0 (GPL570)) were extracted from
the Gene Expression Omnibus (GEO) from the https://www.ncbi.nlm.nih.gov/geo/
website, using the GEO accession numbers listed in Supplementary Table 2. Patient
characteristics are reported in Supplementary Table 1. Data were analysed as described
in the Methods section. All the other data supporting the ﬁnding of this study are
available within the article and its supplementary information or from the corre-
sponding author upon reasonable request.
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